Eledon Pharmaceuticals, Inc. Stock News

IRVINE, Calif., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of

Northern Trust Corp boosted its position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) by 106.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 32,116 shares of the companys stock after purchasing an additional 16,588 shares during the quarter. Northern Trust Corp owned about 0.22% of [] The post Northern Trust Corp Purchases 16,588 Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) appeared first on ETF Daily News .

Wall Street brokerages expect Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) to announce earnings of ($0.80) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Eledon Pharmaceuticals earnings. The lowest EPS estimate is ($0.92) and the highest is ($0.74). The company is expected to issue its next earnings results on []

Eledon Pharmaceuticals (NASDAQ:ELDN) had its price objective decreased by research analysts at HC Wainwright from $35.00 to $25.00 in a research note issued on Wednesday, The Fly reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 391.16% from the stock’s previous close. Several other […]

Wall Street analysts forecast that Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) will announce earnings per share of ($0.77) for the current quarter, according to Zacks. Zero analysts have provided estimates for Eledon Pharmaceuticals earnings. The highest EPS estimate is ($0.64) and the lowest is ($0.94). The firm is expected to announce its next earnings results on Tuesday, []

Eledon Pharmaceuticals, Inc. (ELDN) CEO David-Alexandre Gros on Q3 2021 Results - Earnings Call Transcript

Presentation to focus on potential use of AT-1501 in kidney transplantation as well as research collaboration between Eledon and CareDx to help assess the efficacy of Eledon's investigational AT-1501

Management to host conference call and webcast at 4:30 pm ET Management to host conference call and webcast at 4:30 pm ET

IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for pe

IRVINE, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for pe

IRVINE, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for p

Eledon Pharmaceuticals (ELDN) CEO David-Alexandre Gros on Q2 2021 Results - Earnings Call Transcript

Management to host conference call and webcast at 4:30 pm ET Management to host conference call and webcast at 4:30 pm ET

Interim data expected in late 2022 in a multicenter, open label study to replace tacrolimus with AT-1501

IRVINE, Calif., July 02, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for pe